Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Delphine Rea , Shanti Ame , Marc Berger (1) , Jean-Michel Cayuela , Aude Charbonnier , Valérie Coiteux , Pascale Cony-Makhoul , Viviane Dubruille , Stéphanie Dulucq , Gabriel Etienne , Laurence Legros , Franck Nicolini , Catherine Roche-Lestienne , Martine Escoffre-Barbe , Martine Gardembas , Agnès Guerci-Bresler , Hyacinthe Johnson-Ansah , Françoise Rigal-Huguet , Philippe Rousselot , François-Xavier Mahon

1 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias

Domaines: Hématologie

Delphine Rea, Shanti Ame, Marc Berger, Jean-Michel Cayuela, Aude Charbonnier, et al.. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer, 2018, 124 (14), pp.2956 - 2963. ⟨10.1002/cncr.31411⟩. ⟨hal-01860448⟩